Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Change in Accured Expenses (2016 - 2025)

Northwest Biotherapeutics' Change in Accured Expenses history spans 16 years, with the latest figure at $551000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $551000.0 for Q4 2025, up 37.06% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (down 33.53% YoY), and the annual figure for FY2025 was $5.9 million, down 33.53%.
  • Change in Accured Expenses for Q4 2025 was $551000.0 at Northwest Biotherapeutics, down from $1.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.6 million in Q3 2024 to a low of -$5.6 million in Q2 2024.
  • The 5-year median for Change in Accured Expenses is $1.1 million (2023), against an average of $924800.0.
  • Peak annual rise in Change in Accured Expenses hit 2027.72% in 2024, while the deepest fall reached 554.26% in 2024.
  • Year by year, Change in Accured Expenses stood at $1.9 million in 2021, then grew by 16.6% to $2.2 million in 2022, then tumbled by 216.33% to -$2.6 million in 2023, then skyrocketed by 115.42% to $402000.0 in 2024, then skyrocketed by 37.06% to $551000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $551000.0, $1.8 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.